Hiromasa Hideshima

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis

Kenji Ishitsuka, Teru Hideshima, Makoto Hamasaki et al. · Blood · 2005 · 169 citations · Full text

Medicine, Oncology, Pharmacology +16

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

Teru Hideshima, Klaus Podar, Dharminder Chauhan et al. · Oncogene · 2004 · 132 citations

Medicine, Oncology, Pharmacology +14

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

Teru Hideshima, Laurence Catley, Noopur Raje et al. · British Journal of Haematology · 2007 · 102 citations · Full text

Medicine, Oncology, Pharmacology +17

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

Teru Hideshima, Constantine S. Mitsiades, Hiroshi Ikeda et al. · Blood · 2010 · 50 citations · Full text

Medicine, Cell Biology, Oncology +13

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-β inhibitors

Teru Hideshima, Dharminder Chauhan, Kenji Ishitsuka et al. · Oncogene · 2005 · 45 citations

Medicine, Oncology, Pharmacology +12